Stock EYEG KIORA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kiora Pharmaceuticals, Inc.

Equities

EYEG

US49721T5074

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
4.4 USD -0.90% Intraday chart for Kiora Pharmaceuticals, Inc. +1.15% -6.41%
Jul. 02 Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes CI
Jun. 25 Kiora Pharmaceuticals Appoints Roger A. Goldberg to its Scientific Advisory Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes
CI
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals Board of Directors
AQ
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
NE
Kiora Pharmaceuticals Appoints Roger A. Goldberg to its Scientific Advisory Board
CI
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
NE
Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease
AQ
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M
MT
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
NE
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
NE
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa
NE
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study
AQ
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
NE
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
NE
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
NE
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
NE
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
NE
HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating
MT
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYEG Stock
  4. News Kiora Pharmaceuticals, Inc.